Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Investigation of the Safety, Tolerability and Immunological Effects of T Lymphocytes Transduced With an Anti-Lewis Y (LeY) Chimeric Antigen Receptor Gene (LeY CAR T) in Patients With LeY Antigen Expressing Advanced Solid Tumours

Next Previous
X
Search
Trial Profile

A Phase I Investigation of the Safety, Tolerability and Immunological Effects of T Lymphocytes Transduced With an Anti-Lewis Y (LeY) Chimeric Antigen Receptor Gene (LeY CAR T) in Patients With LeY Antigen Expressing Advanced Solid Tumours

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-Lewis-Y transduced T cells (Primary) ; Fludarabine; Loratadine; Paracetamol; Promethazine; Promethazine
  • Indications Solid tumours
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 03 May 2021 Status changed from recruiting to active, no longer recruiting.
    • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 20 Feb 2019 Planned number of patients changed from 30 to 24.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top